Matthew Krummel

Matthew F. Krummel (Max Krummel) is a Professor in the Pathology Department at University of California, San Francisco. He is known for Systems Immunology and studies mechanisms that regulate the immune system.

Career
Krummel holds the Robert E. Smith Endowed Chair in Pathology and is the Chair of the UCSF ImmunoX Initiative. His lab (krummellab) uses real-time imaging to launch and test hypotheses related to how the immune system processes information and makes decisions. His recent discoveries include determining features of T cell membrane biology and how the movement of immune cells governs their ability to efficiently survey for antigens. Additionally, his research has revealed archetypal collections of immune systems in cancer, namely those involving networks of cells built around stimulatory dendritic cells.

Krummel developed a novel industry consortium-funded project (immunoprofiler.org) that unites studies of cancer indications to understand the biology of individual patients and founded a microscopy ‘collaboratory’ at UCSF. He also founded the ImmunoX initiative, together with other UCSF faculty, which is a radical collaboration platform focused on methods and data sharing as a means to accelerate discovery and cures.

Krummel co-founded Foundery Innovations, a novel biotechnology venture fund and studio that translates early-stage drug concepts through extensive academic-industry collaborations, most recently with the University of California, San Francisco, and the University of Arizona. He founded Pionyr Immunotherapeutics where he discovered new next-generation immunotherapeutics targeting myeloid cells. In the lab of James P. Allison at UC Berkeley, Krummel conducted key studies on the function of the protein CTLA-4; together they developed and described the first CTLA-4 inhibitors. They subsequently collaborated to apply the same inhibitors in tumor models, providing data on the blockade of inhibitory receptors can augment tumor immune responses, the basis for the 2018 Nobel Prize in Medicine and Physiology as well as the first patents for anti-CTLA-4 checkpoint blockade.

Krummel received his Ph.D. at the University of California, Berkeley, and completed his postdoctoral studies at Stanford University.

Honors

 * 2020 Dial Fellow, Emerson Collective.
 * 2009 Fellow of the American Asthma Foundation.
 * 2005 Leukemia and Lymphoma Foundation, Career Award.
 * 2004 Cancer Research Institute, Investigator Award.

Positions and employment

 * 2021 – Present Co-Founder and Managing Member, Foundery Innovations.
 * 2015 – May 2021 Founder and Founding Chief Executive Officer, Pionyr Immunotherapeutics.
 * 2018 – Present Co-Founder and Inaugural Chair, ImmunoX Initiative, University of California at San Francisco.
 * 2012 – Present Professor, Department of Pathology, University of California at San Francisco.
 * 2006 – Present Faculty Director, Biological Imaging Development Center, University of California at San Francisco

Selected publications

 * CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995 Aug 01; 182(2):459-65. Krummel MF, Allison JP. PMID 7543139; PMCID: PMC2192127.
 * Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22; 271(5256):1734-6. Leach DR, Krummel MF, Allison JP. PMID 8596936.
 * Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 05; 24(5):541–550. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. PMID 29686425; PMCID: PMC5998822.
 * Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. PMID 25446897; PMCID: PMC4254577.
 * A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 08; 24(8):1178–1191. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. PMID 29942093; PMCID: PMC6475503.